Clinical Practice Guideline

for

AORTIC VALVE STENOSIS

Developed for the

Aerospace Medical Association

by their constituent organization

American Society of Aerospace Medicine Specialists

 

 

Overview: Aortic stenosis (AS) usually occurs at the level of the aortic valve.  Supravalvular and subvalvular forms of AS exist but are unusual congenital defects unlikely to present as a new diagnosis in an adult military aviator/aircrew.  These would be addressed aeromedically on a case-by-case basis.  Valvular AS has several causes.  In older adults the most common is senile AS, an aging-related calcifying, degenerative process.  In the military aviator/aircrew population the most common cause will be associated bicuspid aortic valve.  AS will still be unusual in military aviator/aircrew with bicuspid aortic valve because this complication usually occurs in middle-aged or older patients.

 

Bicuspid aortic valve (BAV) occurs in 1-2% of the general U.S. population and is the most common congenital cardiac malformation, excluding mitral valve prolapse.  The prevalence of BAV has been about 0.6% in the United States Air Force (USAF) database of Medical Flight Screening echocardiograms (echo) performed on pilot training candidates.  Over 70% of BAV subjects will develop some degree of aortic stenosis (AS) and/or aortic insufficiency (AI) during their lifetime.  Additionally, 30-40% will require surgical placement of a prosthetic aortic valve during their lifetime, predominantly after the age of 45 years.

 

Aeromedical Concerns: While the diagnosis may be suspected by careful auscultation, AS is primarily an echocardiographic (echo) diagnosis.  On echo AS is graded by a combination of mean pressure gradient across the stenotic valve and calculated valve area.  Grading categories are mild, mild-to-moderate, moderate and severe.  Aeromedical concerns for AS include infective endocarditis, progression to significant stenosis and requirement for aortic valve replacement or repair.  The prognosis of mild AS is good for at least five years after diagnosis.  Once AS has progressed to moderate or severe, aeromedical and clinical concerns also include sudden cardiac death, syncope, angina and dyspnea.  Angina may occur in the absence of significant coronary atherosclerosis.  Dyspnea is due to left ventricular dysfunction.  Event rates are 5% and 10% per year for asymptomatic and symptomatic moderate AS, respectively.  Event rates are considerably higher for severe AS.  Mild-to-moderate AS has normal expected event rates for 1-3 years, but represents AS that is likely progressing toward moderate and later severe AS.  At this level of stenosis, maintenance of normal cardiac output under +Gz load is a potential concern, prompting restriction from high performance flying duties.

 

Medical Work-up: An initial waiver can be considered following the review and/or evaluation by the Aeromedical Consultation Service (ACS).  Please refer to items A through D, listed below, as the most commonly requested clinical data.

A. Aeromedical summary (AMS).

B. Copy of the local echo report and videotape or CD copy of the echo (required for ACS confirmation of the diagnosis).

C. Additional local cardiac testing is not routinely required but may be requested in individual cases.

 

D. Copies of reports and tracings of any other cardiac tests performed locally for clinical assessment (e.g. electrocardiogram (ECG), treadmill, Holter monitor).

 

Waiver renewal requires an interval AMS with particular attention to clinical signs and symptoms.  No studies are required prior to the ACS evaluation for renewal except for FCIII renewal for BAV with trace AI and no AS.  In that case a local echocardiogram needs to be sent to the ACS for review.  If studies were accomplished during routine work-up, submit with waiver package.

 

Civil Aviation Medicine (Federal Aviation Administration): The FAA grants medical certification for all classes for aortic stenosis.  The follow up requirements are a yearly echocardiogram.  Once the gradient across the aortic valve reaches 40 mm Hg or the valve area is less than 1.0 cm2 the airman is denied and will not gain medical certification until they have a valve replacement. 

 

Aeromedical Disposition (military): Table 1 is a summary of the clinical manifestations and most common requirements for the separate flying class (FC) duties.

 

Table 1.  Summary of Degree of Aortic Stenosis and ACS Requirements.

 

Associated Levels of Aortic Stenosis (AS)

Flying Class

Waiver Issued

 

Waiver Authority

 

Required ACS Review and/or ACS Evaluation

mild AS

 

FCI and IA

 

 

FC II and FC III

No

AETC

 

Yes

MAJCOM

FCI/IA: ACS evaluation

 

 

FCII/III: ACS evaluation

mild-to-moderate AS

 

FC IIA

(low G- aircraft)

 

FC III

(low G- aircraft)

Yes

AFMSA

 

 

Yes

MAJCOM

FC II:  ACS evaluation

 

 

 

FC III:  ACS evaluation

 

> moderate AS

All Flying Classes

No

N/A

MEB required

 

Initially, waiver will typically be valid for one year with ACS reevaluation required for waiver renewal consideration.  If AS is mild and appears stable after several ACS evaluations, waiver recommendation by the ACS may be extended to two to three years.  Waiver for mild-to-moderate AS will be valid for one year. 

 

 

Aeromedical Disposition (civilian):

In the FAA once the valve has been replaced the airman is required to be grounded for six months immediately following the surgery.  At that time the airman must undergo a maximal nuclear stress test for either first- or second-class certification and a plain Bruce for third-class.  The airman will be required to present the hospital admission and discharge summaries, operative reports and results of any cardiac catheterization at this time as well.  In addition to the stress testing all airmen will be required to provide a current status report listing medications, 2-D echocardiogram, 24 hour Holter monitoring, lipid panel and fasting blood sugar.  None of this testing could have been performed prior to the conclusion of the 6 month observation period.  All first- and second-class airmen have their cases reviewed by a panel of aerospace cardiologists.  This panel makes recommendations as to the risk o sudden incapacitation. 

 

Follow up testing is required yearly for all classes.  It consists of current status report, twelve lead electrocardiogram tracings, 2-D echocardiogram, lipid panel and fasting blood sugar. 

In the civil sector airmen are permitted to fly while being treated with Warfarin anticoagulation.  Should the airman require Warfarin anticoagulation for a mechanical valve they are required to have International Normalized Ratios of between 2.5 and 3.5. 

 

The FAA also permits the airman with aortic stenosis to be treated with the Ross Procedure.  This is a procedure where the aortic valve and pulmonary valves are removed.  The individual then receives their own pulmonary valve in place of the aortic valve and a mechanical valve is placed in the pulmonary valve’s place.  The main purpose for this procedure is that it avoids the necessity for Warfarin anticoagulation.  The initial and recertification requirements are entirely the same as with the aortic valve replacement. 

 

 

Waiver Experience (military): In the US Air Force, 25 cases have been submitted for waiver consideration since May 2002 with the diagnosis of bicuspid aortic valve or aortic stenosis.  Of that total, 22 were granted a waiver to begin or continue aviation duties for an acceptance rate of 88%.

 

Waiver Experience (civilian): As of March 15, 2007 currently issued airmen with mechanical aortic valve replacement: first-class 33, second-class 33, and third-class 139.  Currently issued airmen with tissue aortic valve replacement: first-class 36, second-class 35, and third-class 172. 

 

 

References.

 

1.  Kruyer WB. Cardiology. In: Rayman RB, ed. Clinical Aviation Medicine, 3rd ed. New York: Graduate Medical Publishing, LLC, 2000; 180-88.

 

2.  Kruyer WB, Gray GW, Leding CJ. Clinical aerospace cardiovascular medicine.  In: DeHart RL, Davis JR eds. Fundamentals of Aerospace Medicine, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2002; 348-49 and 352.

 

3.  Bonow RO, chair. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). J Am Coll Cardiol.  32(5):  1486-588, Nov 1998.

 

4.  Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda conference:  Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities.  Task force 2:  Acquired valvular heart disease.  J Am Coll Cardiol.  24(4):  874-80, Oct 1994.

 

 

March 19, 2007